Stabilizing alkylglycoside compositions and methods thereof
View Patent ↗The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
1. A pharmaceutical composition for increasing stability, reducing aggregation or reducing immunogenicity of parathyroid hormone (PTH) or an analog thereof comprising:
PTH or the analog thereof; and
a stabilizing agent comprising at least one alkylglycoside, wherein the alkylglycoside is selected from the group consisting of dodecyl-β-D-maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, and sucrose mono-tetradecanoate.
2. The composition of claim 1 , wherein the PTH analog is PTH (1-34) or PTH (3-34).
3. The composition of claim 1 , further comprising a buffering agent.
4. The composition of claim 1 , wherein the alkylglycoside is dodecyl-β-D-maltoside.
5. The composition of claim 1 , wherein the alkylglycoside has a critical micelle concentration (CMC) of less than about 1 mM.
6. The composition of claim 5 , wherein the alkylglycoside has a CMC of less than about 0.5 mM.
7. The composition of claim 1 , further comprising a mucosal delivery-enhancing agent selected from the group consisting of an aggregation inhibitory agent, a charge-modifying agent, a pH control agent, a degradative enzyme inhibitory agent, a mucolytic or mucus clearing agent, and a chitosan.
8. The composition of claim 7 , wherein the mucosal delivery-enhancing agent is a chitosan.
9. The composition of claim 1 , further comprising benzalkonium chloride.
10. The composition of claim 1 , further comprising a membrane penetration-enhancing agent selected from the group consisting of a surfactant, a bile salt, a phospholipid additive, a mixed micelle, a liposome, a carrier, an alcohol, an enamine, a nitric oxide donor compound, a long-chain amphipathic molecule, a small hydrophobic penetration enhancer, a sodium or a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin or beta-cyclodextrin derivative, a medium-chain fatty acid, a chelating agent, an amino acid or salt thereof, an N-acetylamino acid or salt thereof, an enzyme degradative to a selected membrane component and any combination thereof.
11. The composition of claim 1 , further comprising a modulatory agent of epithelial junction physiology.
12. The composition of claim 1 , further comprising a vasodilator agent.
13. The composition of claim 1 , further comprising a selective transport-enhancing agent.
14. The composition of claim 1 , wherein the composition is in a lyophilized form.
15. The composition of claim 14 , wherein the lyophilized composition retains greater than 50% biological activity upon reconstitution.
16. The composition of claim 1 , wherein the stability of the composition is determined by determining the bioactivity of the PTH or the analog thereof in an in vivo or in vitro assay.
17. The composition of claim 15 , wherein the lyophilized composition further comprises a bulking agent selected from the group consisting of collagen, alginate, and mannitol.
18. The composition of claim 14 , wherein the lyophilized composition is reconstituted prior to administering to a mammalian subject.
19. The composition of claim 1 , wherein the composition is formulated for parenteral, intranasal, pulmonary, or buccal delivery.
20. A method for increasing stability of parathyroid hormone (PTH) or an analog thereof comprising:
admixing parathyroid hormone (PTH) or the analog thereof, a stabilizing agent and a buffering agent to form a composition, wherein the stabilizing agent is at least one alkylglycoside surfactant, wherein the alkylglycoside is selected from the group consisting of dodecyl-β-D-maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, and sucrose mono-tetradecanoate, thereby increasing the stability of the parathyroid hormone (PTH) or the analog thereof.
21. The method of claim 20 , wherein the PTH analog is PTH (1-34) or PTH (3-34).
22. The method of claim 20 , wherein the alkylglycoside is dodecyl-β-D-maltoside.
23. The method of claim 20 , wherein the alkylglycoside has a critical micelle concentration (CMC) of less than about 1 mM.
24. The method of claim 23 , wherein the alkylglycoside has a CMC of less than about 0.5 mM.
25. The method of claim 20 , wherein the composition further comprises a mucosal delivery-enhancing agent selected from the group consisting of an aggregation inhibitory agent, a charge-modifying agent, a pH control agent, a degradative enzyme inhibitory agent, a mucolytic or mucus clearing agent, and a chitosan.
26. The method of claim 25 , wherein the mucosal delivery-enhancing agent is a chitosan.
27. The method of claim 20 , wherein the composition further comprises benzalkonium chloride.
28. The method of claim 20 , wherein the composition further comprises a membrane penetration-enhancing agent selected from the group consisting of a surfactant, a bile salt, a phospholipid additive, a mixed micelle, a liposome, a carrier, an alcohol, an enamine, a nitric oxide donor compound, a long-chain amphipathic molecule, a small hydrophobic penetration enhancer, a sodium or a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin or beta-cyclodextrin derivative, a medium-chain fatty acid, a chelating agent, an amino acid or salt thereof, an N-acetylamino acid or salt thereof, an enzyme degradative to a selected membrane component and any combination thereof.
29. The method of claim 20 , wherein the composition further comprises a modulatory agent of epithelial junction physiology.
30. The method of claim 20 , wherein the composition further comprises a vasodilator agent.
31. The method of claim 20 , wherein the composition further comprises a selective transport-enhancing agent.
32. The method of claim 20 , wherein the composition is lyophilized after admixing.
33. The method of claim 32 , wherein the composition retains greater than 50% biological activity upon reconstitution.
34. The method of claim 20 , further comprising determining the bioactivity of the PTH or the analog thereof in an in vivo or in vitro assay.
35. The method of claim 20 , wherein the composition further comprises a bulking agent selected from the group consisting of collagen, alginate, and mannitol.
36. The method of claim 32 , further comprising reconstituting the composition prior to administering the composition to a mammalian subject.
37. The method of claim 20 , further comprising determining the stability of the composition by light scatter.
38. The composition of claim 1 , wherein the alkylglycoside consists of dodecyl-β-D-maltoside.
39. The method of claim 20 , wherein the alkylglycoside consists of dodecyl-β-D-maltoside.